Oppenheimer Comments on IDEAYA Biosciences’ Q3 2019 Earnings (NASDAQ:IDYA)

Share on StockTwits

IDEAYA Biosciences (NASDAQ:IDYA) – Equities researchers at Oppenheimer issued their Q3 2019 earnings per share (EPS) estimates for IDEAYA Biosciences in a report released on Wednesday, October 16th. Oppenheimer analyst K. Degeeter anticipates that the company will earn ($0.68) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $17.00 target price on the stock. Oppenheimer also issued estimates for IDEAYA Biosciences’ Q4 2019 earnings at ($0.69) EPS, FY2019 earnings at ($2.79) EPS, Q1 2020 earnings at ($0.75) EPS, Q2 2020 earnings at ($0.81) EPS, Q3 2020 earnings at ($0.83) EPS, Q4 2020 earnings at ($0.87) EPS and FY2020 earnings at ($3.26) EPS.

Separately, Robert W. Baird assumed coverage on IDEAYA Biosciences in a research report on Monday, September 9th. They issued an “outperform” rating and a $30.00 price objective for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. IDEAYA Biosciences has an average rating of “Buy” and a consensus target price of $19.20.

NASDAQ:IDYA opened at $5.75 on Monday. The business has a fifty day simple moving average of $7.77. The company has a debt-to-equity ratio of 0.05, a current ratio of 18.94 and a quick ratio of 18.95. IDEAYA Biosciences has a 1 year low of $4.89 and a 1 year high of $16.90.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Monday, August 12th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.66).

A number of large investors have recently added to or reduced their stakes in IDYA. Perceptive Advisors LLC purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $11,369,000. Laurion Capital Management LP purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $199,000. Monashee Investment Management LLC purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $354,000. Point72 Asset Management L.P. purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $1,948,000. Finally, Boxer Capital LLC purchased a new position in shares of IDEAYA Biosciences in the second quarter valued at $7,612,000. Hedge funds and other institutional investors own 25.12% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Featured Story: Cryptocurrencies

Earnings History and Estimates for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Catalyst Capital Advisors LLC Purchases 1,400 Shares of Malibu Boats Inc
Catalyst Capital Advisors LLC Purchases 1,400 Shares of Malibu Boats Inc
22,000 Shares in Teradata Co.  Purchased by Catalyst Capital Advisors LLC
22,000 Shares in Teradata Co. Purchased by Catalyst Capital Advisors LLC
Catalyst Capital Advisors LLC Buys New Shares in JetBlue Airways Co.
Catalyst Capital Advisors LLC Buys New Shares in JetBlue Airways Co.
Catalyst Capital Advisors LLC Acquires New Stake in Ligand Pharmaceuticals Inc.
Catalyst Capital Advisors LLC Acquires New Stake in Ligand Pharmaceuticals Inc.
Catalyst Capital Advisors LLC Sells 1,950 Shares of O’Reilly Automotive Inc
Catalyst Capital Advisors LLC Sells 1,950 Shares of O’Reilly Automotive Inc
Boston Advisors LLC Has $3.15 Million Holdings in T-Mobile Us Inc
Boston Advisors LLC Has $3.15 Million Holdings in T-Mobile Us Inc


© 2006-2019 Ticker Report